We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Fastforward Innovations Limited | LSE:FFWD | London | Ordinary Share | GG00BRK9BQ81 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.25 | 8.00 | 8.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
01/2/2019 23:25 | The answer to your question is Yes this will take us by surprise. One day some massive news on one of our investments will cause the share price to rise to a new level. We have a number of investments that could spark that rise so the future is very bright for FFWD. | 888icb | |
01/2/2019 16:48 | This is soon gonna take us all by surprise isn't it...... isn't it ? | rickyl1 | |
24/1/2019 22:44 | Factom have now confirmed that Factom-captured evidence helped win a copyright infringement case in the Chinese Internet Court between video platform giant Tiktok (where have you been if you haven’t heard of them!)and @Baidu_Inc, the world's 8th largest internet company. Huge huge news...won’t be this price much longer. | jonesyboy 27 | |
22/1/2019 23:23 | The twitter boys calling this perfectly well ahead of the news as per usual.. | jonesyboy 27 | |
22/1/2019 12:03 | One question: why FFWD doesn't produce any "quarterly assets report value"? I feel that they should. | alamaison5 | |
22/1/2019 07:19 | The Factom and TikTok case another huge advert for Factom | brave dave | |
21/1/2019 23:00 | A very quiet day today with just 64000 shares traded. Looks like positions have been taken and investors are awaiting the several items of news that should arrive soon regarding existing investments. Possibly even new investments in the cannabis sector if speculation on another bb proves to be accurate. | 888icb | |
15/1/2019 23:01 | The rise continues UP 5.26% today on volume of 1.5 Million. News has finally arrived on one investment showing a significant gain on our investment. I hope the news will start to come regularly now so we can get back to a much higher share price. | 888icb | |
15/1/2019 22:59 | I sold a good position from 9.5p. Still have a 100k left. | ayesha4 | |
15/1/2019 19:09 | Thanks Kristin I, there was a 80000 trade at 11.83,ithought you got lucky at that price, but it must have been someone else. Good buy on your part nevertheless, gl. | thelogman | |
15/1/2019 15:55 | 13-13.5p Way higher than 9p lows but miles lower than 30p highs Do I buy or wait for a shake | dave4545 | |
15/1/2019 15:54 | Great stuff! A few more smiling faces with this one but the inevitable leak with shares moving strongly ahead before this was announced. FastForward Innovations Limited Juvenescence Series B Funding 15/01/2019 3:45pm UK Regulatory (RNS & others) Fastfwd Innov (LSE:FFWD) Intraday Stock Chart Today : Tuesday 15 January 2019 Click Here for more Fastfwd Innov Charts. TIDMFFWD RNS Number : 1754N FastForward Innovations Limited 15 January 2019 15 January 2019 FastForward Innovations Ltd ("FastForward" or the "Company") Juvenescence Limited completes first tranche of Series B Funding Secures investment of US$46 million The Board of AIM-traded FastForward Innovations Limited, trading under the symbol FFWD, ("FastForward", the "Company" or "FFWD"), is pleased to announce that investee company Juvenescence Limited ("Juvenescence") has completed the first tranche of its planned US$100-125 million funding round. In aggregate Juvenescence has closed on subscriptions from new and existing investors to raise US$46 million at a price of US$24.70 per share. The price of the Series B funding round values Juvenescence at a price of US$400 million and is at a 58 per cent. premium to the price at which the Company invested in the Juvenescence Series A funding round in June 2018 (see 19 June 2018 announcement). At the price per share of the Series B funding round, the Company's holding of 128,205 shares of Juvenescence have an implied value of approximately US$3.2 million, representing an increase of approximately US$1.2 million from the Company's Series A investment. Commenting on the close of the Series B funding round Lorne Abony, FastForward's Chief Executive Officer, noted: "We are delighted with the progress Juvenescence is making with the pipeline of drugs, therapies and technologies they are developing. Having spent time with the company's management in the past few weeks in San Francisco I share their optimism in relation to near-term potential of the company. The successful initial public offer of Age-X Therapeutics Inc. (NYSE:AGE), in which Juvenescence has a 46% interest, is a great example of the expertise Juvenescence brings to drug development companies. The reaction of the investor community to the AgeX listing demonstrates the potential for the longevity industry, in North America and, we hope, in Europe. We look forward to updating shareholders in due course with further positive news from the Juvenescence portfolio of assets." About Juvenescence Juvenescence Limited is a biotech company focused on therapies to increase healthy human longevity. It was founded in 2017 by Jim Mellon, Dr. Greg Bailey, Dr. Declan Doogan, Anthony Chow, and Alexander Pickett. The Juvenescence team are highly experienced drug developers, and serial entrepreneurs with a track record of success in life sciences and drug development. Juvenescence is focused on developing therapeutics that alter ageing or age-related diseases. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of ageing and creates the opportunity to develop therapeutics now that can slow, halt or potentially reverse elements of ageing. The Juvenescence founders and management team have an extensive track record of successfully developing drugs for a range of diseases. Further details regarding Juvenescence are available at its website www.juvenescence.ltd | niggle | |
15/1/2019 10:15 | pleased to see a bit of renewed interest. | hazl | |
15/1/2019 08:44 | i think the order was worked at 12.25 p, will check.... so at 13.46 ; 80000 ; 0.1225 for £9800 settlement | kristini2 | |
14/1/2019 22:02 | Another positive day UP 9.2%. FFWD starting to show long awaited signs of life in anticipation of some major news.It would be good to see it back to at least the 15p Placing price before news lands. | 888icb | |
14/1/2019 18:21 | What price did you get Kristin I, if you Don,t mind me asking. | thelogman | |
14/1/2019 18:18 | Which cretin voted my post down, obviously not invested here. Well done Kristin I nice buy. | thelogman | |
14/1/2019 17:42 | added another 80000 shares today.... just seen the contract note, Go ffwd !! should averaged down at 9.5p.... but the past two day price action looks promising ! | kristini2 | |
14/1/2019 17:08 | News this week Ricky by the looks of it. Volume is the key here and it is picking up and new investors coming in now. Think more will follow anticipating the start of the news flow. | thelogman | |
14/1/2019 11:44 | Be a good time for some news. | rickyl1 | |
14/1/2019 11:25 | Good to see this rise continuing currently UP 12.5% on volume of 500000. | 888icb | |
14/1/2019 11:16 | nice move and on small volumes.... | kristini2 | |
14/1/2019 10:06 | Some nice share price movement at last. Could be the news stacking up. Leaks ? | rickyl1 | |
14/1/2019 00:52 | A 12.7% rise on Friday which I hope will be continued this week. There is so much pending news on several investments each of which should be potentially massive in their own right. It is difficult to comprehend why the share price is not a lot higher. | 888icb |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions